Information Provided By: 
Fly News Breaks for July 17, 2017
EXAS
Jul 17, 2017 | 06:43 EDT
BTIG analyst Sean Lavin raised his price target for Exact Sciences to $45 saying he feels good about test volume in Q2. The analyst believes consistent quarterly beats, potential upside to the total addressable market through greater displacement of colonoscopies and maybe a move into younger patients as well as earlier on-boarding of major payors point to a "solid" 2018 for the company. He reiterates a Buy rating on shares of Exact Sciences.
News For EXAS From the Last 2 Days
There are no results for your query EXAS
